LCTX Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
Company profile
Ticker
LCTX
Exchange
Website
CEO
Brian Culley
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...
Former names
BIOTIME INC
SEC CIK
Corporate docs
IRS number
943127919
LCTX stock data
()
News
Lineage Stock Gains After Licensing Pact With Immunomic Therapeutics For Cancer Immunotherapy Platform
20 Apr 21
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics For An Allogeneic Cell-Based Cancer Immunotherapy Based On Its VAC Platform; Co. To Receive $2M Upfront Payment And Up To $67M In Milestones Plus Royalties
20 Apr 21
Lineage Cell Therapeutics Says OpRegen Data Update To Be Featured At 2021 Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting
12 Apr 21
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021
31 Mar 21
ROCE Insights For Lineage Cell Therapeutics
31 Mar 21
Press releases
Thinking about buying stock in Microvision, Lineage Cell Therapeutics, vTv Therapeutics, electroCore, or Arcadia Biosciences?
20 Apr 21
Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform
20 Apr 21
Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?
31 Mar 21
Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use
29 Mar 21
Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy
23 Mar 21
Investment data
Securities sold
Number of investors
Calendar
11 Mar 21
21 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.59M | 32.59M | 32.59M | 32.59M | 32.59M | 32.59M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 1.96M | 2.4M | 1.88M | 1.65M |
Cash used (since last report) | n/a | n/a | 7.26M | 8.88M | 6.96M | 6.09M |
Cash remaining | n/a | n/a | 25.33M | 23.7M | 25.62M | 26.49M |
Runway (months of cash) | n/a | n/a | 12.9 | 9.9 | 13.6 | 16.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 21 | Culley Brian M | Common Shares, no par value | Payment of exercise | Dispose F | No | No | 2.35 | 5,343 | 12.56K | 195,709 |
31 Mar 21 | Culley Brian M | Common Shares, no par value | Option exercise | Aquire M | No | No | 2.35 | 15,450 | 36.31K | 201,052 |
31 Mar 21 | Culley Brian M | RSU Common Shares | Option exercise | Dispose M | No | No | 0 | 15,450 | 0 | 77,250 |
30 Mar 21 | Alexandra Hernandez | Common Shares, no par value | Sell | Dispose S | No | No | 2.23 | 6,000 | 13.38K | 0 |
30 Mar 21 | Alexandra Hernandez | Common Shares, no par value | Option exercise | Aquire M | No | No | 0.6919 | 6,000 | 4.15K | 6,000 |
30 Mar 21 | Alexandra Hernandez | Employee Stock Option Common Shares | Option exercise | Dispose M | No | No | 0.6919 | 6,000 | 4.15K | 39,200 |
15 Mar 21 | Culley Brian M | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 2.43 | 1,165,100 | 2.83M | 1,165,100 |
15 Mar 21 | Hogge Gary S. | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 2.43 | 419,500 | 1.02M | 419,500 |
15 Mar 21 | Leavitt Chase C. | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 2.43 | 699,100 | 1.7M | 699,100 |
15 Mar 21 | Alexandra Hernandez | Employee Stock Option Common Shares | Grant | Aquire A | No | No | 2.43 | 42,700 | 103.76K | 42,700 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
34.1% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 87 |
Opened positions | 87 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares |
Current |
---|---|
Total value | 98.65M |
Total shares | 55.06M |
Total puts | 26.5K |
Total calls | 528.3K |
Total put/call ratio | 0.1 |
Largest owners |
Shares | Value |
---|---|---|
Broadwood Capital | 34.01M | $59.85M |
Vanguard | 6.21M | $10.93M |
Defender Capital | 4.74M | $8.34M |
Prescott General Partners | 1.85M | $3.26M |
BLK Blackrock | 1.6M | $2.82M |
Geode Capital Management | 1.07M | $1.87M |
ExodusPoint Capital Management | 807.61K | $1.42M |
Bridgeway Capital Management | 680.84K | $1.2M |
Two Sigma Investments | 547.22K | $963K |
Two Sigma Advisers | 509.87K | $897K |
Financial report summary
?Competition
International Stem Cell • Astellas Pharma • IVERIC bio • VistaGen Therapeutics • Astellas Pharma • Apellis Pharmaceuticals • Biostage • RPEContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
AAO, Abeona, ACOR, Acorda, adjacent, admitted, advice, advisor, Aeglea, Analyst, Anderson, anesthesiologist, annuity, answer, Aravive, Asia, AstraZeneca, ATM, Atreca, atrophic, attending, attorney, AZN, bailey, banker, Barbara, Bellicum, beneficiary, Bernardino, biochemistry, biographical, biosimilar, Biotie, BITI, Boston, boundary, Brandi, Brisbane, CAA, Calithera, CamberView, career, Carlson, carryover, Celldex, Ceplene, CFA, chair, Chartered, Chase, Chimerix, Citigroup, CMRO, COBRA, Colorado, column, Comarco, concert, continuum, Cornell, corroborated, coupon, Coventry, COVID, Crohn, CTOA, Deborah, delegate, Deputy, Diego, dihydrochloride, diligence, disallowed, discretionary, Doctor, don, Drexel, duly, dying, Edward, effectuated, Elan, exacerbation, Exit, expert, Farrell, Fate, Finland, Floor, footprint, forgivable, forgiven, furlough, Gary, Genocea, Greenbelt, Greenway, Harpoon, headquartered, hearing, histamine, Hogge, honorary, hTERT, hypothesized, Icahn, ICI, Idera, ILS, immunology, Immusol, inevitably, Infinity, inflammatory, Inovio, InterMune, intimate, irreversible, ITMN, Johnson, Lampe, Latham, Leavitt, LLM, loan, logistical, Lynch, magnitude, Magtrol, Mallinckrodt, Marsh, Mast, McLennan, mechanical, Merrill, Mersana, microenvironment, MNK, motion, MSTX, mulroy, natalizumab, nationwide, NBIX, Neon, Neurocrine, NewLink, nominating, nurse, occupy, Odonate, ODT, Orange, Orphagen, outlined, outperformed, paragraph, paused, Paycheck, pecuniary, peer, pension, Pepperdine, PJT, plc, PPP, PPV, predominately, printing, prolonged, QCOR, QIMR, Queensland, Questcor, ratify, Rauth, resignation, resigned, restarted, Revance, RHHBY, risky, Robert, Roche, russell, RVNC, salary, Santa, Savara, SBA, Secretary, setback, shelter, Shire, SHPG, shut, shutdown, signature, simple, Southern, Spero, STAA, STAAR, stipend, Stradling, survey, SVRA, SWCH, Switch, Syndax, Synlogic, Tang, tenure, thereunto, tie, TM, transformed, TSR, Turku, twelfth, TXMD, Tysabri, UCI, UCSD, undersigned, UNITY, unprecedented, unspent, untreated, usability, user, ventilator, wealth, Wharton, Wirth, Yocca, Zeneca, Ziopharm
Removed:
advertisement, aesthetic, analyzing, Ascendance, assay, assumption, attestation, attribution, avoiding, background, bankruptcy, biocompatibility, biopsy, brown, Bulletin, caption, chemistry, Coast, collectability, confirmatory, Conversely, core, COSO, deconsolidation, distributed, DNA, doubtful, earliest, endpoint, exclusively, expensing, expired, expiry, feeling, flat, forfeiture, Francisco, gelatin, generating, heart, HIV, hyaluronate, IIB, immaterial, impacting, imposing, induced, inInternal, input, internally, ISO, iTR, lab, lapse, LifeMap, lowering, mimic, muscle, obtainable, offshore, opening, orin, otherin, plasma, PMA, Premvia, prepare, principle, prosecuting, prospective, PureStem®progenitor, ratification, reacquisition, remeasured, renew, repatriation, repealing, SAB, Selection, sodium, specification, straight, sublicense, sublicensed, sublicensee, supplier, telomere, tendon, territorial, Teva, thereon, thiol, unadjusted, unaffiliated, underStaff, underwritten, unilaterally, unique, unqualified, utilizing, vascular, veterinary, waive
Financial reports
10-K
2020 FY
Annual report
11 Mar 21
10-Q
2020 Q3
Quarterly report
4 Nov 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
28 Apr 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K/A
2018 FY
Annual report (amended)
1 May 19
Current reports
8-K
Departure of Directors or Certain Officers
29 Mar 21
8-K
Departure of Directors or Certain Officers
26 Mar 21
8-K
Other Events
23 Mar 21
8-K
LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
11 Mar 21
8-K
Results of Operations and Financial Condition
5 Mar 21
8-K
Departure of Directors or Certain Officers
20 Jan 21
8-K
Regulation FD Disclosure
6 Jan 21
8-K
Lineage Cell Therapeutics Presents New Opregen® Data for Dry Amd with Ga at 2020 American Academy of Ophthalmology Annual Meeting
16 Nov 20
8-K
Other Events
12 Nov 20
8-K
Lineage Cell Therapeutics Reports Third Quarter 2020
4 Nov 20
Registration and prospectus
S-3
Shelf registration
11 Mar 21
S-8
Registration of securities for employees
11 Mar 21
S-3
Shelf registration
11 Mar 21
424B5
Prospectus supplement for primary offering
5 Mar 21
S-3
Shelf registration
30 Apr 20
S-8
Registration of securities for employees
8 Aug 19
425
Business combination disclosure
28 Feb 19
424B3
Prospectus supplement
4 Feb 19
S-4/A
Registration of securities issued in business combination transactions (amended)
13 Jan 19
S-4
Registration of securities issued in business combination transactions
4 Jan 19
Proxies
DEF 14A
Definitive proxy
9 Aug 20
DEFA14A
Additional proxy soliciting materials
9 Aug 20
DEFA14A
Additional proxy soliciting materials
14 Jun 19
DEF 14A
Definitive proxy
14 Jun 19
DEF 14A
Definitive proxy
28 Mar 18
DEFA14A
Additional proxy soliciting materials
28 Mar 18
PRE 14A
Preliminary proxy
18 Mar 18
DEFR14A
Revised proxy
12 Jul 17
DEFA14A
Additional proxy soliciting materials
29 Jun 17
PRER14A
Preliminary revised proxy
29 Jun 17
Other
EFFECT
Notice of effectiveness
22 Mar 21
EFFECT
Notice of effectiveness
22 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
CORRESP
Correspondence with SEC
16 Mar 21
UPLOAD
Letter from SEC
15 Mar 21
UPLOAD
Letter from SEC
15 Mar 21
EFFECT
Notice of effectiveness
11 May 20
CORRESP
Correspondence with SEC
5 May 20
UPLOAD
Letter from SEC
5 May 20
CT ORDER
Confidential treatment order
13 Dec 17
Ownership
4
Lineage Cell Therapeutics / Alexandra Hernandez ownership change
1 Apr 21
4
Lineage Cell Therapeutics / Brian M Culley ownership change
1 Apr 21
4
Lineage Cell Therapeutics / Brian M Culley ownership change
17 Mar 21
4
Lineage Cell Therapeutics / Gary S. Hogge ownership change
17 Mar 21
4
Lineage Cell Therapeutics / Chase C. Leavitt ownership change
17 Mar 21
SC 13D/A
Lineage Cell Therapeutics / BROADWOOD PARTNERS ownership change
16 Mar 21
4/A
Lineage Cell Therapeutics / NEAL C BRADSHER ownership change
16 Feb 21
5
Lineage Cell Therapeutics / ALFRED D KINGSLEY ownership change
12 Feb 21
3
Lineage Cell Therapeutics / Alexandra Hernandez ownership change
22 Jan 21
SC 13D/A
OncoCyte / Lineage Cell Therapeutics ownership change
8 Jan 21
Patents
APP
Utility
Methods for Telomere Length and Genomic Dna Quality Control Analysis In Pluripotent Stem Cells
8 Apr 21
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.
GRANT
Utility
Methods of screening embryonic progenitor cell lines
16 Feb 21
Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion.
APP
Utility
Retinal Pigment Epithelium Cell Compositions
6 Jan 21
Presented herein are ready to administer (RTA) retinal pigment epithelium (RPE) cell therapy compositions for the treatment of retinal degenerative diseases and injuries.
GRANT
Utility
Methods and formulations for orthopedic cell therapy
14 Dec 20
Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.
GRANT
Utility
Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells
17 Aug 20
The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells.
Transcripts
2020 Q4
Earnings call transcript
12 Mar 21
2020 Q3
Earnings call transcript
4 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
7 May 20
2019 Q4
Earnings call transcript
12 Mar 20
2019 Q3
Earnings call transcript
12 Nov 19
2019 Q2
Earnings call transcript
8 Aug 19
2019 Q1
Earnings call transcript
10 May 19
2018 Q4
Earnings call transcript
14 Mar 19
2018 Q3
Earnings call transcript
8 Nov 18
Reddit threads
Morning Update for Tuesday, 04/20/21
20 Apr 21
Expected Biotech News 20 April 2021 to 17 June 2021 and PDUFA List for 26 April 2021 to 17 July 2021 (Updated Lists)
17 Apr 21
ACRX participated in Benzinga Biotech Small Cap Conference today with an overview of their products. Fireside chat with Dr. Pamela Palmers coming up at 11:35. See last link to live conference.
24 Mar 21
Daily Discussion Thread - March 11th, 2021
11 Mar 21
Daily Discussion Thread - March 10th, 2021
10 Mar 21
What stocks to buy with $1000 for a buy and forget UGMA account for my kid?
9 Mar 21
Daily Discussion Thread - March 9th, 2021
9 Mar 21
Daily Discussion Thread - March 8th, 2021
8 Mar 21
Upcoming Biotech Catalysts - 1Q 2021
5 Feb 21
Daily Discussion Thread - November 4th, 2020
4 Nov 20